Jim Reddoch, PhD, PhD

Jim Reddoch, PhD has more than 25 years of experience in biopharma investing. As Royalty Pharma's CSO & EVP, Investments, he leverages his science background to identify trends and find new investment opportunities. He joined Royalty Pharma as EVP, Research, in 2008. Prior to joining Royalty Pharma, Dr. Reddoch led healthcare research at FBR Capital Markets. Previously, Dr. Reddoch was a biotechnology analyst at Bank of America and CIBC World Markets. Dr. Reddoch serves on the boards of The Leukemia and Lymphoma Society (LLS) and the New York Academy of Sciences. He is on the MSK Leadership Council as well as the review board for MSK's Technology Development Investment Fund. He is co-chairman of Life Science Cares New York and is on the national board of Life Science Cares. Dr. Reddoch is on the President's Advisory Committee on Biology and Medicine at Brown University, as well as the President's Advisory Committee of Tyler Jacks' Break Through Cancer initiative. Dr. Reddoch has a BA from Furman University, a PhD in biochemistry and molecular genetics from UAB, and was a postdoctoral fellow at Yale University.